One of the most prominent areas where Amneal faces competition is in the genericpharmaceuticals market. Multiple sources from synapse‐provided documents consistently identify key players that dominate this segment: Teva is frequently cited as a principal competitor by Amneal.
Looking back on genericpharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Amneal (NASDAQ: AMRX) and its peers. The genericpharmaceutical industry operates on a volume-driven, low-cost business model, producing bioequivalent versions of branded drugs once their patents expire.
View AmnealPharmaceuticals's top competitors like Aurobindo Pharma, Cadence Pharmaceuticals - Now a Part of Mallinckrodt Pharmaceuticals, and Hikma Pharmaceuticals.
AmnealPharmaceuticals, Inc. (AMRX) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.
In early December 2025, AmnealPharmaceuticals announced that the FDA had approved its epinephrine injection USP and multiple new complex generics, including cyclosporine ophthalmic emulsion, albuterol sulfate inhalation aerosol, and an extended-release Parkinson’s therapy, CREXONT. This cluster of approvals opens access to U.S. markets worth billions of dollars in aggregate annual branded ...
See how AmnealPharmaceuticalscompares to similar products. AmnealPharmaceuticals 's top competitors include ImmuNovX Biotech, Endo International, and Sandoz.
